Lanicemine

Lanicemine
Clinical data
ATC code	none;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name (1S)-1-Phenyl-2-pyridin-2-ylethanamine;
CAS Number	153322-05-5;
PubChem CID	9794203;
IUPHAR/BPS	7681;
ChemSpider	7969970;
UNII	9TMU325RK3;
CompTox Dashboard (EPA)	DTXSID30870011 ;
Chemical and physical data
Formula	C13H14N2
Molar mass	198.269 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N[C@H](C1=CC=CC=C1)CC2=NC=CC=C2;
	InChI InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m0/s1; Key:FWUQWDCOOWEXRY-ZDUSSCGKSA-N;

Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression. Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects. However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.